@FierceMedDev: Roche ekes out diagnostics growth as diabetes biz falters. More | Follow @FierceMedDev
@MarkHFierce: Another J&J hip lawsuit is settled. Will the company resolve the 11,000-plus suits that remain outstanding? Story | Follow @MarkHFierce
@MichaelGFierce: Trending from FierceDrugDelivery: Mini-pancreas grown from stem cells has implications for future insulin delivery. Article | Follow @MichaelGFierce
> Surgical devicemaker Theragenics' ($TGX) shareholders have approved a $68.3 million bid by private equity outfit Juniper to buy the company. Item
> OrthoSensor gained a CE mark for its system designed to aid surgeons during total knee replacement surgeries. Story
> Therapeutic hyperthermia doesn't increase the risk of stent thrombosis in patients who experience out-of-hospital cardiac arrest before a stent procedure. Story
> Futura Medical won a CE mark for a new erection-enhancing condom lined with a special gel. Story
> Enzo Biochem ($ENZ) will start selling a number of DiaSorin advanced diagnostic tools, with an option to expand its offerings in the future. Item
> The Cleveland Clinic's pick for the top innovations of 2014 include a computer-assisted personalized sedation system and a bionic eye. Story
Biotech News
@FierceBiotech: Industry Voices: Clinical trial transparency--time for some carrot as well as more stick? Feature | Follow @FierceBiotech
@JohnCFierce: Danish biotech Egalet pitches $69M IPO on Nasdaq. News | Follow @JohnCFierce
@DamianFierce: Fresh off a staggering FDA rejection, Wright is spending $80M on an implant outfit. Story | Follow @DamianFierce
@EmilyMFierce: AstraZeneca, Harvard's Wyss Institute partner to advance 'Organs-on-Chips' drug-testing tech. Item | Follow @EmilyMFierce
> Aragon begets Seragon as VCs bankroll $30M cancer drug spinoff. Article
> Roche: Forget mega-mergers, focus on a new round of blockbuster bolt-ons. Story
> Amarin shares shrivel after FDA experts spurn Vascepa. Item
> AstraZeneca, Amgen Crohn's drug runs into PhII 'logistical' snafu. Report
Pharma News
@FiercePharma: Top news yesterday: Teva halts Israeli layoffs amid pressure from labor, gov't. Report | Follow @FiercePharma
@CarlyHFierce: Eisai to recruit 200 new sales reps for amped-up Belviq push. ICYMI yesterday | Follow @CarlyHFierce
> FDA experts vote against expansion of Amarin's Vascepa. News
> Pharma dealmakers, listen up: Ireland may close a popular tax loophole. Story
> Roche CEO scuttles Novartis merger talk. More
Pharma Manufacturing News
@EricPFierce: Another gut check for Amarin and its fish oil drug Vascepa: FDA panel votes against wider use. News | Follow @EricPFierce
> In turnabout, U.K. tells Wockhardt to recall 5 drugs. Report
> Federal case over drug shortage comes to an end. Story
> Teva reconsiders production cuts in Israel. Item
> B. Braun recalls product after organic particulate found. More
> Genzyme expanding U.S. plant opened last year. Article
Vaccines News
> Cost of rabies vaccine limiting use in Africa. Report
> Merck, Sanofi report on first vaccine in European pilot project. More
> IOM releases modeling software for vaccine prioritization. Item
> Novartis cuts jobs in California as eastward shift continues. More
> India to expand use of pentavalent vaccine after safety thumbs-up. Article
> U.K. court orders sisters to receive MMR vaccine. Story